Feasibility of Photofrin II as a radiosensitizing agent in solid tumors - Preliminary results

Onkologie

Volumn 29, Issue 11, 2006, Pages 514-519

  Schaffer, Moshe ^a,b   Ertl Wagner, Birgit ^b   Schaffer, Pamela Manuela ^a   Kulka, Ulrike ^a   Jori, Giulio ^c   Wilkowski, Ralf ^a   Hofstetter, Anton ^a   Dühmke, Eckhart ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Ionizing irradiation; Photofrin II; Radiosensitizer

Indexed keywords

PHOTOFRIN II;

ADENOCARCINOMA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; FEASIBILITY STUDY; FOLLOW UP; GLIOMA; HUMAN; IONIZING RADIATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIZATION; SKIN MANIFESTATION; SOLID TUMOR; SPHENOID SINUS; TUMOR VOLUME;

DIHEMATOPORPHYRIN ETHER; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 33750354860     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095979     Document Type: Article

References (26)

1. McBride WH, Withers HR: Biologic basis of radiation therapy; in Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology. Philadelphia, Lippincott Williams and Wilkins, 2004, pp. 96-136.
2. Wasserman TH, Chapman JD: Radiation response modulation, part A: chemical sensitizers and protectors. In: Perez CA Brady LW (eds): Principles and Practice of Radiation Oncology. Philadelphia, Lippincott Williams and Wilkins, 2004, pp. 663-679.
3. Stewart F, Baas P, Star W: What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? Radiother Oncol 1998;48: 233-248.
4. McDonald IJ, Dougherty TJ: Basic principles of photodynamic therapy. J Porphyrins Phthalocyanines 2001;5:105-129.
5. Schmidt-Erfurth U, Miller JW, Sickenberg M: Photodynamic therapy for choroidal neurovascularization in a phase II study. Assoc Res Vision Ophthalmology 1997;38:74-75.
6. Foote CS: Definition of type I and type II photosensitized oxidation. Photochem Photobiol 1991;54: 659.
7. Byrne CJ, Marshallsay LV, Ward AD: The composition of Photofrin II. J Photochem Photobiol B 1990;6:13-27.
8. Schaffer M, Schaffer PM, Corti L, Sotti G, Hofstetter A, Jori G, Dühmke E: Photofrin II as an efficient radiosensitizing agent in an experimental tumor. Onkologie 2001;24:482-485.
9. Schaffer M, Schaffer PM, Corti L, Gardiman M, Sotti G, Hofstetter A, Jori G, Dühmke E: Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model. J Photochem Photobiol B 2002;66:157-164.
10. Schaffer M, Schaffer PM, Jori G, Corti L, Sotti G, Hofstetter A, Dühmke E: Radiation therapy combined with photofrin or 5-ALA: effect on Lewis sarcoma tumor lines implanted in mice. Preliminary results. Tumori 2002;88:407-410.
11. Schaffer M, Schaffer PM, Hofstetter A, Duhmke E, Jori G: On the double role of photofrin as a photo- and a radio-sensitising agent: a possible new combination therapy for tumours. Photochem Photobiol Sci 2002;1:438-439.
12. Kulka U, Schaffer M, Siefert A, Schaffer PM, Ölsner A, Hofstetter A, Kassab K, Dühmke E, Jori G: Photofrin as a radiosensitizer in an in vitro cell survival assay. Biochem Biophys Res Commun 2003;311:98-103.
13. Schwartz S: Porphyrins and porphyrin precursors in human and experimental porphyria. Fed Proc 1955;14:717-722.
14. Schwartz S, Absolon K, Vermund H: Some relationships of porphyrins. X-rays and tumors. University of Minnesota Medical Bulletin 1955;27:7-13.
15. Cohen L, Schwartz S: Modification of radiosensitivity by porphyrins. II. Transplanted rhabdomyosarcoma in mice. Cancer Res 1966;26: 1769-1773.
16. Kostron H, Swartz MR, Miller DC, Martuza RL: The interaction of hematoporphyrin derivative, light, and ionizing radiation in a rat glioma model. Cancer 1986;57:964-970.
17. Vogeser M, Schaffer M, Egeler E, Spöhrer U: Development of an HPLC method for monitoring of Photofrin II therapy. Clin Biochem 2005;38:73-78.
18. Dougherty TJ, Cooper MT, Mang TS: Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg Med 1990;10:485-488.
19. Schaffer M, Schaffer PM, Panzer M, Wilkowski R, Duhmke E: Porphyrias associated with malignant tumors: results of treatment with ionizing irradiation. Onkologie 2001;24:170-172.
20. Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M: Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998;108: 962-967.
21. Gomer CJ, Ferrario A: Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumour model. Cancer Res 1990;50:3985-3990.
22. Orenstein A, Kostenich G, Roitman L, Kopolovic Y, Ehrenberg B, Malik Z: A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Br J Cancer 1996;73:937-944.
23. Sessler JL, Miller RA: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000;59: 733-739.
24. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 1999;45: 981-989.
25. Bernhard EJ, Mitchell JB, Deen D, Cardell M, Rosenthal DI, Brown JM: Reevaluating gadolinium(III) texaphyrin as a radiosensitizing agent: Cancer Res 2000;60:86-91.
26. O'Hara JA, Douple EB, Abrams MJ, Picker DJ, Giandomenico CM, Vollano JF: Potentiation of radiation-induced cell kill by synthetic metalloporphyrins. Int J Radiat Oncol Biol Phys 1989;16: 1049-1052.